EDIT Editas Medicine Inc

Price (delayed)

$3.75

Market cap

$309.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.34

Enterprise value

$283.54M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
EDIT's EPS is up by 21% year-on-year but it is down by 13% since the previous quarter
Editas Medicine's net income has decreased by 16% QoQ but it has increased by 6% YoY
Editas Medicine's quick ratio has shrunk by 53% YoY and by 16% QoQ
EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
82.48M
Market cap
$309.29M
Enterprise value
$283.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.33
Price to sales (P/S)
4.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.23
Earnings
Revenue
$67.03M
EBIT
-$213.03M
EBITDA
-$207.22M
Free cash flow
-$171.54M
Per share
EPS
-$2.34
Free cash flow per share
-$2.08
Book value per share
$2.82
Revenue per share
$0.81
TBVPS
$4.68
Balance sheet
Total assets
$384.8M
Total liabilities
$152.79M
Debt
$38.7M
Equity
$232.01M
Working capital
$212.05M
Liquidity
Debt to equity
0.17
Current ratio
3.85
Quick ratio
3.76
Net debt/EBITDA
0.12
Margins
EBITDA margin
-309.1%
Gross margin
100%
Net margin
-288.6%
Operating margin
-317.8%
Efficiency
Return on assets
-42.3%
Return on equity
-62.6%
Return on invested capital
-62.2%
Return on capital employed
-68.6%
Return on sales
-317.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
-0.79%
1 week
7.45%
1 month
-4.34%
1 year
-58.33%
YTD
-62.98%
QTD
-19.7%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$67.03M
Gross profit
$67.03M
Operating income
-$213.02M
Net income
-$193.45M
Gross margin
100%
Net margin
-288.6%
The net margin has soared by 73% YoY but it has contracted by 21% from the previous quarter
EDIT's operating margin has surged by 72% year-on-year but it is down by 19% since the previous quarter
Editas Medicine's net income has decreased by 16% QoQ but it has increased by 6% YoY
EDIT's operating income is down by 15% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
1.33
P/S
4.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.23
EDIT's EPS is up by 21% year-on-year but it is down by 13% since the previous quarter
EDIT's P/B is 63% below its 5-year quarterly average of 3.6 and 33% below its last 4 quarters average of 2.0
EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter
The P/S is 89% less than the 5-year quarterly average of 40.7 and 63% less than the last 4 quarters average of 12.6
The revenue has declined by 3.4% since the previous quarter

Efficiency

How efficient is Editas Medicine business performance
EDIT's return on sales has surged by 72% year-on-year but it is down by 19% since the previous quarter
The ROE has decreased by 32% from the previous quarter and by 14% YoY
Editas Medicine's ROA has decreased by 26% from the previous quarter and by 5% YoY
EDIT's return on invested capital is down by 17% since the previous quarter but it is up by 9% year-on-year

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
EDIT's total assets is 152% higher than its total liabilities
Editas Medicine's quick ratio has shrunk by 53% YoY and by 16% QoQ
The current ratio has plunged by 52% YoY and by 16% from the previous quarter
The debt is 83% less than the equity
The company's debt to equity has surged by 89% YoY and by 42% QoQ
EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.